Introduction
Patients with advanced or treatment-refractory Hodgkin disease and non-Hodgkin lymphoma (NHL) and patients with multiple myeloma (MM) may be successfully treated with high-dose chemotherapy followed by autologous transplantation of PBSCs. [1] [2] [3] Successful engraftment of PBSCs is well correlated with the number of CD34 þ stem cells infused. 4 PBSCs are mobilized into the PB by treating patients with granulocyte-CSF (G-CSF) for 5-7 days before leukapheresis. Circulating stem cells can also be increased with disease-specific, non-myeloablative chemotherapy, often in combination with G-CSF (reviewed in Bensinger et al 5 ). The minimum number of CD34 þ cells required for a single auto-SCT is generally considered to be 2-2.5 Â 10 6 CD34 þ cells/kg. 4, 5 However, a significant proportion of MM or lymphoma patients fail to mobilize adequate numbers of PBSCs after conventional mobilization strategies (that is G-CSF with or without chemotherapy) and cannot proceed to the planned auto-SCT. In fact, depending on prior treatment with stem cell toxic drugs, underlying disease, age, prior radiotherapy, and bone marrow involvement, the failure rate with current strategies is estimated to be between 5 and 40%. 5, 6 However, there is a general consensus that PBSC mobilization failures are underreported, as they typically may not include patients who do not proceed to PBSC collection (for example infectious complications during neutropenia). In addition, it is not clear from the literature whether patients who do not yield the optimal number of cells (generally considered to be between 4 and 6 Â 10 6 CD34 þ cells/kg recipient body weight for a single transplant) should be qualified as partial failures/ successes. Depending on the therapeutic goal and the definition of 'poor mobilizer', failure rates are expected to be higher than those historically reported in the literature. Mobilization failures leave patients with suboptimal alternative treatment strategies (for example bone marrow collection, allogeneic transplantation, further mobilization attempts, and so on).
Plerixafor (formerly AMD3100) is a CXCR4 chemokine antagonist that has been shown to increase the number of circulating CD34 þ cells in healthy volunteers and cancer patients when administered alone or with G-CSF. 7 When plerixafor (0.16 or 0.24 mg/kg) was given after 5 days of G-CSF (10 mg/kg/day) to NHL and MM patients, the apheresis yields were significantly higher when compared with patients receiving G-CSF alone. 8 Of note, the combination of plerixafor and G-CSF successfully rescued 66% of MM and lymphoma patients who had previously failed at least one round of mobilization with G-CSF with or without chemotherapy. 9 Two Phase III, multicenter, randomized, double-blinded, placebo-controlled studies were recently conducted to evaluate the safety and efficacy of plerixafor plus G-CSF versus placebo plus G-CSF to mobilize, front line, CD34
þ stem cells in patients with NHL and MM, respectively. 10, 11 In both studies, the combination of plerixafor plus G-CSF was safe and well tolerated, and the efficacy results showed that plerixafor and G-CSF mobilized significantly higher numbers of hematopoietic stem cells than G-CSF alone.
However, most European transplant centers routinely use chemotherapy and G-CSF to reduce the tumor burden and to mobilize PBSCs at the same time. In patients with MM, chemotherapy is given primarily for mobilization purposes. 12 A wide variety of chemotherapeutic agents are used, but not all are equally effective with regard to mobilization. Cy is one of the most common agents, either used alone or as part of combination regimens, but dosing standards are not (yet) established, ranging from 1 to 7 g/m 2 . 12 In lymphoma patients, second line salvage chemotherapy, is often used, in association with G-CSF, to mobilize PBSCs. 13 Very few data are available on the safety and efficacy of the administration of plerixafor added to G-CSF, after chemotherapy, to mobilize PBSCs. 14 In this article, we report 13 MM and lymphoma patients, candidates for autologous PBSC transplantation who were classified as 'poor mobilizers' or 'no mobilizers' at all based on daily monitoring of CD34 þ cell count during the recovery phase after chemotherapy and G-CSF. Our results suggest that the addition of plerixafor to G-CSF after chemotherapy was safe and provide some evidence of efficacy in patients planned to undergo auto-SCT who were failing PBSC mobilization.
Patients and methods

Study design
MM and lymphoma patients, considered as potential candidates for auto-SCT, received a mobilizing regimen of disease-specific chemotherapy and G-CSF. At the time of hematological recovery, daily monitoring of circulating CD34 þ cells was started. Patients were then considered 'poor mobilizers' when the concentration of PB CD34 þ cells was always lower than 10 cells/mL and/or they were predicted to have inadequate PBSC collection to proceed to the planned transplantation program. Thus, plerixafor (0.24 mg/kg; Genzyme Europe BV, Naarden, The Netherlands) was added to G-CSF under a compassionate use program for 13 consecutive MM and lymphoma patients.
The aim of the study was to assess whether the use of plerixafor after chemotherapy would be safe and would allow adequate PBSC collection in patients defined as 'poor mobilizers' during mobilization based on CD34 þ cell count.
Study patients
Patient characteristics are summarized in Table 1 . Three young MM patients (median age 45 years) were enrolled in the study. They received induction chemotherapy with either four cycles of thalidomide (Thalidomide, Celgene, Summit, NJ, USA) and dexamethasone (TD) (Patient 3) 15 or two to four cycles of bortezomib (Velcade, Janssen Cilag, Beerse, Belgium), thalidomide (Celgene) and dexamethasone (VTD) (Patients 4 and 5, respectively). 16 None of them had been treated with lenalidomide or local radiotherapy and none was in CR at the time of PBSC mobilization. Patient 4 had a creatinine level of 5.9 mg/dL with a creatinine clearance of 8 mL/min and was submitted to chronic dialysis treatment three times a week while showing resistant disease after two cycles of VTD.
Ten heavily pre-treated lymphoma patients with a median age of 58 years were also included in the study. They all had relapsed after induction chemotherapy with MACOP-B regimen 17 ) followed by radioimmunotherapy with ibritumomab tiuxetano (Zevalin, Bayer Schering Pharma AG, Berlin, Germany, 14.8 MBq/kg; one infusion) at the time of first relapse for Patient 2 followed by two cycles of IEV chemotherapy when the second relapse occurred. Patients 6, 8, 12 , and 13 were treated with two cycles of R-ICE 22 as salvage chemotherapy whereas Patient 7 received five cycles of R-Bendamustine. 23 Patient 9 received eight cycles of R-CHOP as salvage therapy, whereas Patient 10 was treated with ChIVPP/EVA for six cycles 24 and Patient 11 with six cycles of FCR. 25 Mobilization regimen Disease-specific mobilization regimen was selected according to the institutional guidelines. For PBSC mobilization, patients received: DHAP (dexamethasone 40 mg PO/i.v. Table 1) . G-CSF at 10 mg/kg/day was administered from day 10 and from day 13 after DHAP and ESHAP regimen, respectively, from day 7 after R-ICE and from day 6 after Cy, IEV, and ABVD mobilization regimens. Plerixafor (Genzyme) was administered subcutaneously at 0.24 mg/ kg/day for up to 3 days the evening before the planned leukapheresis.
PBCS collection and transplantation PBSC collection started when the PB CD34 þ cell count was 410/mL after plerixafor administration. Doublevolume leukapheresis (that is two blood volume; DVL) or large-volume leukapheresis (that is three blood volume; LVL) were used, according to the institutional guidelines. A maximum of three leukapheresis for each patient were performed. LVL was performed in 8/10 lymphoma patients. DVL was used in all MM patients and in 2/10 lymphoma patients (Patients 1 and 2).
PBSCs collected were infused after myeloablative conditioning consisting of high-dose melphalan for MM patients (200 or 140 mg/m 2 in patient N.4 due to renal impairment) and BEAM chemotherapy (carmustine (BCNU) 300 mg/m 2 on day -6; etoposide 200 mg/m 2 and citarabine 400 mg/m 2 twice daily on days -5, À4, À3, À2; and melphalan 140 mg/m 2 on day -1) for lymphoma patients. Post transplant G-CSF was administered at 5 mg/kg/day per institutional standards until neutrophil engraftment. Time to neutrophil and platelet recovery was defined as the number of days to achieve an ANC higher than 0.5 Â 10 9 /L (first of three consecutive days) and an unsupported platelet count higher than 20 and 50 Â 10 9 /L.
Statistical analysis
No specific statistical analysis was performed. The result section is purely descriptive for every single patient in Tables 1 and 2 , whereas a graphical presentation of the kinetic of mobilization of CD34 þ cells of representative patients is included.
Results
MM patients
Three MM were treated with Cy to mobilize PBSCs. Starting from day 6 after Cy, G-CSF at 10 mg/kg/day was administered and from day 11 daily monitoring of PBSC mobilization was started. Extensive details on the kinetics of mobilization of CD34 þ cells, G-CSF and plerixafor administration, and stem cell collection(s) are shown in Figure 1 and Table 2 .
Briefly, plerixafor was given to Patients 3 and 5 because PB CD34 þ cell concentration dropped down to 7/mL and 12/mL, respectively, after the initial PBSC collections were felt to be inadequate considering the poor-prognosis disease, the young age and the planned double auto-SCT Overall, all MM patients were able to yield an adequate number of CD34 þ cells to perform the planned auto-SCT with 1-3 leukapheresis (Table 2) . In all three patients, plerixafor was well tolerated and no worsening of renal function was observed during treatment.
Plerixafor-mobilized PBSCs were reinfused, after highdose melphalan and after B1 month from stem cell collection. The time to ANC40.5 Â 10 9 /L was 11, 12, and 13 days, respectively; the time to platelet count 420 Â 10 9 / L was 11, 14, and 13 days, respectively. No documented infectious complications occurred. The time to hospital discharge after PBSC reinfusion was 14, 12, and 13 days, respectively.
Lymphoma patients
All lymphoma patients were considered poor mobilizers based on the low concentration of circulating CD34 þ cells (o10/mL) observed at time of hematological recovery after mobilizing chemotherapy. The detailed description of the kinetics of CD34 þ cell mobilization of one such patient is represented in Figure 2a . Conversely, Patient 7 showed a peak value of 20.8 CD34 þ cells/mL on day 14 from chemotherapy. Stem cell harvest was then started and 0.8 Â 10 6 CD34 þ cells/kg could be collected. The next day (day 15), PB CD34 þ cells decreased to 9.7/mL despite administration of G-CSF resulting in the collection of 1 Â 10 6 CD34 þ cells/kg. On the evening of day 15, the patient then received plerixafor which increased the number of circulating CD34 þ cells up to 47.8/mL and allowed the collection of 1.91 Â 10 6 CD34 þ cells/kg (with a total number of 3.71 Â 10 6 CD34 þ cells/kg) (Figure 2b ). Overall, in lymphoma patients, plerixafor was administered for a median of two injections (range 1-3) allowing the collection, in all patients, of a sufficient number of CD34 þ cells to proceed to auto-SCT (Table 2) . Also in lymphoma patients, treatment with plerixafor was well tolerated and no side effects, potentially related to the drug, were observed.
In all, 2/10 patients (Patients 2 and 9) have already undergone auto-SCT with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery after BEAM conditioning regimen. The time to ANC 40.5 Â 10 9 /L was, in both cases, 11 days; the time to platelet count 420 Â 10 9 /L was 16 and 17 days, respectively. No documented infectious complications occurred. The time to hospital discharge after PBSC reinfusion was 16 and 19 days, respectively.
Discussion
Auto-SCT is an effective anti-tumor strategy in MM and lymphoma. However, a significant proportion of patients, especially if heavily pre-treated and treatment refractory, is not able to mobilize a sufficient number of cells to proceed to transplantation. In Bologna transplant center database, for instance, 25 and 36% of NHL and MM patients, respectively, had been classified as poor mobilizers and failed to undergo subsequent single or double auto-SCT, respectively (Lemoli RM, unpublished data). þ cells/kg (total number of CD34 þ cells/kg ¼ 6.6 Â 10 6 in two apheresis).
The pre-emptive use of plerixafor after chemotherapy A D'Addio et al Various factors have been reported to impact on stem cell mobilization. Low platelet count before mobilization and bone marrow involvement have been reported to be associated with suboptimal mobilization 28, 29 along with the burden of previous chemotherapy. In MM, most retrospective studies addressing mobilization have identified the number of prior regimens, the time to mobilization and prior exposure to alkylating agents like melphalan and/or radiotherapy as predictors of mobilization failure. More- Tables 1 and 2 ) was treated with eight cycles of R-CHOP achieving a CR. She relapsed 14 months later and received two cycles of R-ICE. Stem cell collection was planned to be performed after the second cycle of R-ICE. From day 7, she received G-CSF at a dose of 10 mg/kg/day. On day 15, circulating CD34 Tables 1 and 2 ). She then received five cycles of R-Bendamustine (day 1: Rituximab 375 mg/m 2 , days 2-6: Bendamustine 60 mg/m 2 ). For stem cell mobilization, Cy was given at the dose of 2 g days 1-2 and G-CSF at a dose of 10 mg/kg/day from day 7. On day 14, a WBC count of 16 Â 10 9 /L and a CD34 þ cell count of 20.8/mL was found. Leukapheresis session was started and 0.8 Â 10 6
CD34
þ cells/kg could be collected. The next day (day 15), PB CD34 þ cells decreased to 9.7/mL, despite administration of G-CSF, and the second leukapheresis resulted in the collection of 1 Â 10 6 CD34 þ cells/kg. On the evening of day 15, the patient received plerixafor. The following morning, circulating CD34
þ cells increased to 47.8/mL and 1.91 Â 10 6 CD34 þ cells/ kg could be collected (total number of 3.71 Â 10 6 CD34 þ cells/kg).
Table 2
PBSCs mobilization WBC at baseline (/mL) The pre-emptive use of plerixafor after chemotherapy A D'Addio et al over, novel anti-MM therapies such as lenalidomide have been demonstrated to impair PBSC mobilization. [30] [31] [32] [33] [34] Controversial data have been published on the activity of both thalidomide and bortezomib on stem cell mobilization. However, the impact of these drugs on the ability to proceed to transplantation appears to be minimal. 30, 31 Similarly, in lymphoma patients, prior chemotherapy with drugs like fludarabine, nitrogen mustard, carmustine, lomustine, chlorambucil and busulphan has been shown to cause damage to the stem cell pool and affect stem cell mobilization, whereas cytarabine and vinblastine have been shown to cause limited damage. 35, 36 Moreover, the use of the radioimmunoconjugate Ibritumomab tiuxetano as induction-consolidation therapy may impair subsequent PBSC mobilization.
In this article, the decision to use plerixafor in addition to G-CSF was well weighted against the lack of published data on its use after chemotherapy, considering the potential benefit of autologous transplantation in our patient population.
Poor mobilization was defined when the concentration of PB CD34
þ cells was lower than 10 cells/mL during the recovery phase after chemotherapy and/or the collection of PBSCs was predicted to be inadequate to perform single or double auto-SCT. The timing for plerixafor administration was not planned in advance. The rapid biological activity of plerixafor (that is peak time of CD34 þ cell mobilization occurring 10-12 h after injection) allowed its administration 'on demand', that is when PBSC mobilization was felt to be inadequate, considering WBCs and CD34 þ cell kinetics. After plerixafor treatment, 13/13 patients were able to collect the minimum required cell dose (2 Â 10 6 CD34 þ cells/kg for single auto-SCT) in r3 apheresis. We observed a remarkable fold-increase (median value ¼ 4.7) in the number of circulating CD34 þ cells after plerixafor administration, as shown in earlier trials. 14 Noteworthy, in this group of patients, injection of plerixafor was shown to be safe. We did not observe any clinical adverse events or any variation in laboratory values even in three patients older than 60 years and in one patient undergoing dialysis during mobilization. Noteworthy, in this last patient, the dose of plerixafor was not reduced according to renal failure. In this view, results from a small series of patients with advanced renal failure indicate that plerixafor may be safely used at full dosage to mobilize PBSCs in this difficult patient group. 37 Overall, these findings confirm the safety profile of plerixafor after chemotherapy.
14 Of note, plerixafor administration did not induce any significant alteration of platelet values or hemoglobin level during post-chemotherapy period before stem cell collection.
Although we recognize that our patient population is somewhat heterogeneous and that our data do not come from a prospective trial, but, rather from a compassionate use program, we believe that the results presented here may provide useful information for transplanters as many patients may benefit from the pre-emptive administration of plerixafor during their mobilization course, resulting in saving of unnecessary apheresis procedures, days of hospitalization and improving patients quality of life. Moreover, the identification of proven 'poor mobilizers' during mobilization, based on daily assessment of CD34 þ cell count, may provide a potent tool for early intervention. To this end, future studies should prospectively test welldefined algorithms, perhaps based on WBC and CD34 þ cell count and/or the results of first day collection, to optimize the use of plerixafor after chemotherapy. Whereas we cannot rule out that some of our patients may have mobilized satisfactorily with the continuation of G-CSF alone, it is promising that the highest fold-increase was observed in those patients with o5 circulating CD34 þ cells/mL, suggesting the role of plerixafor in this 'hardto-mobilize' patient population.
At this writing, 5/13 patients have already undergone auto-SCT. Plerixafor-mobilized PBSC engrafted rapidly, and the hematological recovery remained stable after 3, 6, 6, 6, and 11 months of follow-up. Accordingly, the infection rate, red blood cell, and platelet transfusion requirement or supportive care was minimal.
In summary, our results suggest that the addition of plerixafor to chemotherapy and G-CSF may allow the rescue of heavily pre-treated or poor-prognosis NHL and MM patients who need to perform auto-SCT as consolidation therapy but are failing PBSC mobilization.
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